

**VIA EDGAR**

May 25, 2021

Office of Life Sciences  
Division of Corporation Finance  
United States Securities and Exchange Commission  
100 F Street N.E.  
Washington, D.C. 20549

Attn: Irene Paik, Joe McCann, Tara Harkins and Dan Gordon

**Re: Centessa Pharmaceuticals plc  
Acceleration Request for Registration Statement on Form S-1  
File No. 333-255393**

**Requested Date: May 27, 2021**

**Requested Time: 4:00 p.m. Eastern Time**

Ladies and Gentlemen:

Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended, we wish to advise that as of the date hereof, approximately 3,878 copies of the Preliminary Prospectus dated May 24, 2021 were distributed to prospective underwriters, institutional investors and prospective dealers in connection with the above captioned Registration Statement.

We wish to advise you that the participating underwriters have informed us that they have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

We hereby join in the request of the registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:00 p.m. Eastern Time, on May 27, 2021 or as soon thereafter as practicable.

*[Signature page follows]*

---

Very truly yours,

MORGAN STANLEY & CO. LLC  
GOLDMAN SACHS & CO. LLC  
JEFFERIES LLC  
EVERCORE GROUP L.L.C.

As representatives of the Underwriters

MORGAN STANLEY & CO. LLC

By: /s/ Chirag D. Surti  
Name: Chirag D. Surti  
Title: Vice President

GOLDMAN SACHS & CO. LLC

By: /s/ Elizabeth Reed  
Name: Elizabeth Reed  
Title: Managing Director

JEFFERIES LLC

By: /s/ Matthew Kim  
Name: Matthew Kim  
Title: Managing Director, Joint US Head of  
Biopharmaceuticals

EVERCORE GROUP L.L.C.

By: /s/ Francois Maisonrouge  
Name: Francois Maisonrouge  
Title: Senior Managing Director

*[Signature Page to Acceleration Request]*